Qiming Venture Partners
China gene therapy start-up Cure Genetics raises $60m
Advantech Capital has led a USD 60m Series B for Suzhou-based biotech player Cure Genetics. Other investors include Oriza Holdings, Blue Ocean Private Equity, and Qiming Venture Partners.
Biotech player CANbridge drops on debut after $87m HK IPO
CANbridge Pharmaceuticals, a Beijing-based drug developer that focuses on treatments for cancer and rare diseases, lost 27% in value on its Hong Kong trading debut following a HK$685.1 million ($87.8 million) IPO.
Qiming leads $40m round for Allorion Therapeutics
China and US-based precision medicine company Allorion Therapeutics has raised a $40 million Series A round led by Qiming Venture Partners.
China biotech IPOs in Hong Kong to stay strong - AVCJ Forum
The frenzy for Chinese biotech developers listing in Hong Kong is expected to continue well into 2022, industry participants told the AVCJ Private Equity & Venture Forum.
China CRO Tripod raises $156m
Tripod Preclinical Research Laboratories, a China-based contract research organization (CRO) based in Nanjing, has raised RMB1 billion ($156 million) led by Ruihua Capital, Lilly Asia Ventures (LAV) and GL Ventures.
China networking chip specialist Clounix raises $63m
China-based networking chip manufacturer Clounix has raised approximately RMB400 million ($63 million) across angel and pre-Series A rounds.
PE-backed Abbisko trades up after $225m Hong Kong IPO
China-based oncology drug developer Abbisko Therapeutics gained nearly 10% on its Hong Kong trading debut following a HK$1.75 billion ($225 million) IPO.
PE-backed MicroTech Medical targets $254m Hong Kong IPO
MicroTech Medical, a China-based manufacturer of insulin pumps for diabetes sufferers that counts Lilly Asia Ventures (LAV) and Qiming Venture Partners among its investors, is looking to raise up to HK$1.98 billion ($254 million) in a Hong Kong IPO.
China's Broncus raises $215m in IPO, struggles on HK debut
Broncus Holding Corporation, a China-based manufacturer of medical devices used to treat lung diseases, plunged 12.8% on its Hong Kong trading debut following a HK$1.67 billion ($215 million) IPO.
Sofina, CDH wealth platform lead round for China's Petkit
Petkit, a Chinese manufacturer of smart devices for pets such as water and food dispensers, has raised $50 million in a Series D round of funding led by Sofina and CDH Investments' wealth management platform.
China cancer screening specialist raises $99m
China Merchants Capital has led a $99.5 million funding round for Berry Oncology Corporation, an early cancer screening spin-out from China-based genetic testing specialist Berry Genomics.
Asia digital assets platform Matrixport hits $1b valuation
Matrixport, a two-year-old crypto financial services platform based in Singapore, has closed a $100 million Series C round at a valuation of $1 billion.
Deal focus: Neiwai realizes value offline
Vertex Ventures China was adamant that Neiwai should expand offline on leading a Series B for the lingerie brand in 2017. Four years and two rounds later, the strategy is paying off
Carlyle leads $100m Series D for Chinese lingerie brand
Chinese lingerie brand Neiwai has raised a $100 million Series D round led by The Carlyle Group. Vertex Ventures China and Qiming Venture Partners re-upped.
China CRO player raises $50m to support US merger
DMed-Clinipace, a global contract research organization (CRO) with a presence in China, has raised $50 million in an extended Series C round led by Springhill Fund. Rock Springs Capital and Superstring Capital also took part.
China's Qiming targets listed healthcare businesses
Qiming Venture Partners is mobilizing its newly launched public equities unit – and $500 million fund – to participate as an anchor investor in Hong Kong IPOs by Chinese healthcare companies.
PE-backed China dental player files for Hong Kong IPO
Arrail Group, a leading Chinese dental chain that has raised about $400 million in private funding since 2010, has filed for a Hong Kong IPO.
Warburg Pincus leads Series C for China AI drug developer
Insilico Medicine, which leverages artificial intelligence (AI) technology to speed up the drug development process, has closed a $255 million Series C funding round led by Warburg Pincus.
Chinese drug developer Abbisko files for HK IPO
PE-backed Abbisko Therapeutics, which focuses on the discovery and development of innovative and differentiated small molecule oncology therapies, has filed for a Hong Kong IPO.
Deal focus: Content to the masses
Xiaoe Tong gained traction during the pandemic in China as channel for educational content providers, big and small, to reach their customers. It is also a SaaS player that stands firm on product standardization
IDG leads $120m round for China SaaS player Xiaoe Tong
Xiaoe Tong, a Chinese software-as-a-service (SaaS) provider that integrates its products with WeChat, has raised $120 million in Series D funding led by IDG Capital.
China's WeRide closes Series C, hits $3.3b valuation
Chinese autonomous driving company WeRide has achieved a valuation of $3 billion on closing a Series C round of undisclosed size. It comes four months after the company raised $310 million in Series B funding.
China medical tech supplier AMS raises $100m
China and US-based Access Medical Systems (AMS) has raised a $100 million round co-led by Sequoia Capital China and GL Ventures.
Source Code leads Series C for China online insurance broker
Yuanbao, a Chinese online insurance broker, has raised nearly RMB1 billion ($156 million) in Series C funding led by Source Code Capital. Other investors include Cathay Capital, Hike Capital, Northern Light Venture Capital, Qiming Venture Partners, and...